Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...

(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...

Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 2026 ...